Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amphotericin B for visceral leishmaniasis in Nepal
ACTRN12610000130066Phase 3Completed
- Sponsor
- UNICEF
- Start
- Apr 2010
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of liposomal amphotericin b in visceral leishmaniasis (VL), sponsored by UNICEF. Primary endpoint: Efficacy of liposomal amphotericin B. Started Apr 2010; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on ACTRN12610000130066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000130066.